(Alliance News) - Shares rose in Microsaic Systems PLC on Friday, after announcing the development and demonstration of its real-time monitoring mass spectrometry detector, for use in the online production of biotherapeutic drugs.
Shares in the Woking-based MS instruments developer were 15% higher at 0.26 pence on Friday in London.
The new product will use live data transmitted through 'internet of things' devices from the micro-engineered equipment, allowing for the constant monitoring of the production processes, allowing for rapid scaling to large volumes, accelerating the rollout of vaccines and anti-cancer treatments and reducing supervision costs.
"In just a short time we have demonstrated and delivered an efficient automated production scaling methodology to fast-track drugs and vaccines to market, at a lower cost of production and without manual human intervention, whilst maintaining consistent high quality. We are not aware of any other technology that can simultaneously analyse small and large molecules as part of on-line production," said Chief Executive Officer Glenn Tracey.
By Dayo Laniyan; dayolaniyan@alliancenews.com
Copyright 2021 Alliance News Limited. All Rights Reserved.
Microsaic (MSYS)